+

WO2005082398A3 - Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells - Google Patents

Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells Download PDF

Info

Publication number
WO2005082398A3
WO2005082398A3 PCT/US2005/005596 US2005005596W WO2005082398A3 WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3 US 2005005596 W US2005005596 W US 2005005596W WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
hyperinsulinemia
diabetes
diagnosis
protection against
Prior art date
Application number
PCT/US2005/005596
Other languages
French (fr)
Other versions
WO2005082398A2 (en
Inventor
John J Kopchick
Karen T Coschigano
Keith S Boyce
Andres Kriete
Original Assignee
Univ Ohio
Icoria Inc
John J Kopchick
Karen T Coschigano
Keith S Boyce
Andres Kriete
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio, Icoria Inc, John J Kopchick, Karen T Coschigano, Keith S Boyce, Andres Kriete filed Critical Univ Ohio
Priority to AU2005216922A priority Critical patent/AU2005216922A1/en
Priority to EP05713932A priority patent/EP1732582A2/en
Priority to CA002557181A priority patent/CA2557181A1/en
Publication of WO2005082398A2 publication Critical patent/WO2005082398A2/en
Publication of WO2005082398A3 publication Critical patent/WO2005082398A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mouse genes differentially expressed in comparisons of normal vs. hyperinsulinemic, hyperinsulinemic vs. type 2 diabetic, and normal vs. type 2 diabetic muscle by gene chip analysis have been identified, as have corresponding human genes and proteins. The human molecules, or antagonists thereof, may be used for protection against or diagnosis hyperinsulinemia or type 2 diabetes, or their sequelae.
PCT/US2005/005596 2004-02-26 2005-02-24 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells WO2005082398A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2005216922A AU2005216922A1 (en) 2004-02-26 2005-02-24 Diagnosis of hyperinsulinemia and type II diabetes and protection against same based on genes differentially expressed in muscle cells
EP05713932A EP1732582A2 (en) 2004-02-26 2005-02-24 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
CA002557181A CA2557181A1 (en) 2004-02-26 2005-02-24 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54751204P 2004-02-26 2004-02-26
US60/547,512 2004-02-26
US57934204P 2004-06-15 2004-06-15
US60/579,342 2004-06-15

Publications (2)

Publication Number Publication Date
WO2005082398A2 WO2005082398A2 (en) 2005-09-09
WO2005082398A3 true WO2005082398A3 (en) 2006-01-26

Family

ID=34915602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005596 WO2005082398A2 (en) 2004-02-26 2005-02-24 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells

Country Status (4)

Country Link
EP (1) EP1732582A2 (en)
AU (1) AU2005216922A1 (en)
CA (1) CA2557181A1 (en)
WO (1) WO2005082398A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
WO2006063009A2 (en) * 2004-12-07 2006-06-15 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2401401A4 (en) * 2009-02-27 2012-11-28 Verva Pharmaceuticals Ltd A drug identification protocol for type 2 diabetes based on gene expression signatures
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066787A2 (en) * 1999-05-05 2000-11-09 Ohio University Growth hormone-regulatable liver genes and proteins, and uses thereof
WO2004092419A2 (en) * 2003-03-31 2004-10-28 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same (i)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066787A2 (en) * 1999-05-05 2000-11-09 Ohio University Growth hormone-regulatable liver genes and proteins, and uses thereof
WO2004092419A2 (en) * 2003-03-31 2004-10-28 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same (i)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"CLONTECH.PCR-Select differential screening kit. User Manual", CLONTECH, 10 September 2001 (2001-09-10), pages 1 - 35, XP002307356 *
BERNAL-MIZRACHI E ET AL: "GENE EXPRESSION PROFILING IN ISLET BIOLOGY AND DIABETES RESEARCH", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON,, GB, vol. 19, no. 1, 2003, pages 32 - 42, XP008045358, ISSN: 1520-7552 *
CALVO ROSA MARIA ET AL: "Immunohistochemical and morphometric studies of the fetal pancreas in diabetic pregnant rats. Effects of insulin administration", ANATOMICAL RECORD, vol. 251, no. 2, June 1998 (1998-06-01), pages 173 - 180, XP002332470, ISSN: 0003-276X *
COROMINOLA H ET AL: "Identification of novel genes differentially expressed in omental fat of obese subjects and obese type 2 diabetic patients", DIABETES, NEW YORK, NY, US, vol. 50, no. 12, December 2001 (2001-12-01), pages 2822 - 2830, XP002293068, ISSN: 0012-1797 *
GERLACH C ET AL: "PROLIFERATION-ASSOCIATED KI-67 PROTEIN IS A TARGET FOR AUTOANTIBODIES IN THE HUMAN AUTOIMMUNE DISEASE SYSTEMIC LUPUS ERYTHEMATOSUS", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 78, no. 1, January 1998 (1998-01-01), pages 129 - 130, XP002073106, ISSN: 0023-6837 *
LIM H W ET AL: "Identification of differentially expressed mRNA during pancreas regeneration of rat by mRNA differential display", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 299, no. 5, 20 December 2002 (2002-12-20), pages 806 - 812, XP002324520, ISSN: 0006-291X *
PIETILAEINEN T ET AL: "THE IMPORTANT PROGNOSTIC VALUE OF KI-67 EXPRESSION AS DETERMINED BY IMAGE ANALYSIS IN BREAST CANCER", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 122, no. 11, 1996, pages 687 - 692, XP008028143, ISSN: 0171-5216 *
SONE H ET AL: "Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice.", DIABETOLOGIA. JAN 2005, vol. 48, no. 1, January 2005 (2005-01-01), pages 58 - 67, XP002332471, ISSN: 0012-186X *
SURWIT R S ET AL: "Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and AJ mice", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 44, no. 5, May 1995 (1995-05-01), pages 645 - 651, XP004540280, ISSN: 0026-0495 *

Also Published As

Publication number Publication date
WO2005082398A2 (en) 2005-09-09
EP1732582A2 (en) 2006-12-20
CA2557181A1 (en) 2005-09-09
AU2005216922A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
WO2004089396A3 (en) Anti-fungal peptidomimetics
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2007070640A3 (en) Use of roma for characterizing genomic rearrangements
WO2004044168A8 (en) Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
EP1595952A4 (en) Method of estimating antitumor effect of histone deacetylase inhibitor
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2005082398A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
WO2004081043A3 (en) Baff mutants with at least one amino acid substitution and methods of their production
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
EP1186672A3 (en) Polymorphisms in the human organic anion transporter C (OATP-C) gene
WO2007015926A3 (en) Multiparameter flow cytometric cytometric cytotoxicity systems, methods, compositions and kits for evaluating the susceptibility of cancer
WO2006089268A8 (en) Gene and cognate protein profiles and methods to determine connective tissue markers in normal and pathologic conditions
WO2006063009A3 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
WO2007002830A3 (en) Diagnosis of and protection from hyperinsulinemia and type ii diabetes
WO2005110460A3 (en) Diagnosis and treatment methods related to aging, especially in muscle (14.1)
WO2005052182A3 (en) A method of analyzing plasma membrane protein content of cells
WO2004094673A3 (en) Methods for monitoring drug activities in vivo
WO2004081535A3 (en) The establishment of proteome structure profile databases and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2557181

Country of ref document: CA

Ref document number: 2005216922

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005216922

Country of ref document: AU

Date of ref document: 20050224

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005216922

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005713932

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005713932

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载